Compare Medtronic PLC (MDT) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Quantumscape Corp — how do they compare? Medtronic PLC trades at $90.31 (market cap $116.07B), while Quantumscape Corp trades at $6.52 (market cap $3.90B). The key difference: Medtronic PLC is far larger — about 29.8× Quantumscape Corp's market cap, and Medtronic PLC pays a 3.18% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| MDT | QS | |
|---|---|---|
Market Cap | $116.07B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $18.44 |
52-Week Low | $73.75 | $4.89 |
Enterprise Value | $134.82B | $3.11B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
QuantumScape (QS) trades at $6.19, up 1.89% today, with a mixed technical outlook showing bullish oscillators but bearish moving averages. The company remains pre-revenue with significant losses, reporting a net income of -$435.05M in 2025 (company filing, 2025). Recent Q2 2026 earnings beat expectations but highlighted ongoing commercialization delays, with solid-state battery targets pushed to 2029 (The Motley Fool, 2026-08-11).
The stock presents high-risk speculation due to zero revenue and persistent cash burn, offset by potential long-term disruption in battery technology. Analyst sentiment is cautious with 73% hold ratings, reflecting skepticism on near-term execution. Key risks include timeline slippage, funding needs, and competitive pressure in the EV supply chain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
